- Home
- BLND vs MDXG Comparison
BLND vs MDXG Comparison
Compare BLND & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLND
- MDXG
- Stock Information
- Founded
- BLND 2012
- MDXG 2006
- Country
- BLND United States
- MDXG United States
- Employees
- BLND N/A
- MDXG N/A
- Industry
- BLND EDP Services
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- BLND Technology
- MDXG Health Care
- Exchange
- BLND Nasdaq
- MDXG Nasdaq
- Market Cap
- BLND 925.5M
- MDXG 877.4M
- IPO Year
- BLND 2021
- MDXG N/A
- Fundamental
- Price
- BLND $3.50
- MDXG $6.75
- Analyst Decision
- BLND Buy
- MDXG Strong Buy
- Analyst Count
- BLND 7
- MDXG 2
- Target Price
- BLND $4.93
- MDXG $11.50
- AVG Volume (30 Days)
- BLND 1.6M
- MDXG 882.8K
- Earning Date
- BLND 08-07-2025
- MDXG 07-30-2025
- Dividend Yield
- BLND N/A
- MDXG N/A
- EPS Growth
- BLND N/A
- MDXG N/A
- EPS
- BLND N/A
- MDXG 0.27
- Revenue
- BLND $164,949,000.00
- MDXG $352,375,000.00
- Revenue This Year
- BLND N/A
- MDXG $9.55
- Revenue Next Year
- BLND $28.57
- MDXG $11.43
- P/E Ratio
- BLND N/A
- MDXG $25.08
- Revenue Growth
- BLND 15.07
- MDXG 5.34
- 52 Week Low
- BLND $2.37
- MDXG $5.47
- 52 Week High
- BLND $5.53
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- BLND 54.64
- MDXG 55.70
- Support Level
- BLND $3.53
- MDXG $6.57
- Resistance Level
- BLND $3.70
- MDXG $6.99
- Average True Range (ATR)
- BLND 0.14
- MDXG 0.29
- MACD
- BLND 0.01
- MDXG 0.02
- Stochastic Oscillator
- BLND 64.07
- MDXG 81.31
About BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.